India’s Inflection Point Ventures Goes Global with a $110M Fund—and Its First Investment Is Game-Changing
Gurugram-based investment platform Inflection Point Ventures (IPV) just made a massive leap onto the global stage. With the launch of IPV International, a brand-new $110 million fund, IPV is aiming to back early-stage startups across the world—and its first move is already making headlines.
So, what’s the big deal? IPV isn’t just throwing cash at anything. The first company it’s backing is Cellivate Technologies, a Singapore-based startup that’s on a mission to replace fetal bovine serum—a controversial animal product used in lab research—with a patented, ethical alternative powered by magnetic stimulation.
Yeah, that’s science fiction turning into science fact.
$110M Fund Launch Under GIFT City’s Global Framework
IPV International is registered under GIFT City’s IFSCA framework—India’s international finance zone built to attract global capital. This gives IPV the green light to invest globally, with full regulatory backing.
The fund is geared toward early-stage to pre-Series A startups, writing checks between $100K and $1M. With its first close in April 2025, it’s already off to a fast start.
Why Cellivate? Why Now?
Cellivate’s technology could shake up biotech, pharma, and lab-grown meat industries by eliminating the need for animal-derived serum in cell culture. IPV clearly wants to make bold, high-impact bets—starting with a startup that’s both ethically-driven and scientifically advanced.
IPV’s Big Play: From Indian Roots to Global Reach
Vinay Bansal, IPV’s founder and CEO, said the firm is responding to rising interest in cross-border investing and wants to help Indian investors tap into the global startup boom.
With its deep roots in the Indian startup scene and a brand-new international playbook, IPV is aiming to become a serious global VC player—one that finds the next big thing before the rest of the world catches on.
